Clinical Trials Logo

Fibrosis clinical trials

View clinical trials related to Fibrosis.

Filter by:

NCT ID: NCT04803643 Completed - Cystic Fibrosis Clinical Trials

Upper Extremity Exercise Capacity, Muscle Oxygenation, Balance in Patients With Cystic Fibrosis

Start date: March 16, 2021
Phase:
Study type: Observational

The primary aim of the study is to evaluate upper extremity exercise capacity, muscle oxygenation, balance and physical activity level in patients with cystic fibrosis.. The secondary aim of the study is assessment of functional exercise capacity, respiratory function, peripheral and respiratory muscle strength, respiratory muscle endurance, quality of life in patients with cystic fibrosis and compare them with healthy controls.

NCT ID: NCT04798014 Completed - Cystic Fibrosis Clinical Trials

HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy

Start date: May 26, 2021
Phase:
Study type: Observational

This is an observational cohort study, using data from Folia Health and the Cystic Fibrosis Foundation Patient Registry (CFFPR). Individuals taking elexacaftor/tezacaftor/ivacaftor (ETI) may be enrolled through the Folia application. During the 12-month study period, participants will be asked to track their routine treatment and medication usage, daily symptoms, and monthly review with validated patient-reported outcome (PRO) questionnaires. Participants will also be asked to self-report instances of changes to their treatment plan, and pulmonary exacerbations. There are no study-associated site visits.

NCT ID: NCT04790435 Completed - Cirrhosis, Liver Clinical Trials

Acute-On-Chronic Liver Failure In Cirrhotic Patients

Start date: March 1, 2021
Phase:
Study type: Observational

Cirrhosis is a condition characterized by diffuse fibrosis, severe disruption of the intrahepatic arterial and venous flow, portal hypertension and, ultimately, liver cell failure. Traditionally, cirrhosis has been dichotomised in compensated and decompensated, and the transition to decompensated cirrhosis happens when any of the following hallmarks occurs: presence of ascites, variceal haemorrhage and/ or hepatic encephalopathy (HE) . In Egypt, HCV is the main cause of liver cirrhosis followed by HBV

NCT ID: NCT04788173 Completed - Cirrhosis Clinical Trials

Assessment Of Lipid Profile In Cirrhotic Patients

Start date: March 1, 2021
Phase:
Study type: Observational

Cirrhosis is defined anatomically as a diffuse process with fibrosis and nodule formation. It is the result of the fibrogenesis that occurs with chronic liver injury. Lipoproteins are complexes of lipid and proteins that are essential for transport of soluble vitamins Liver cells play a serious task in the regulation of lipid metabolism. The principal location for lipoprotein and cholesterol synthesis is in the liver. In healthy individuals, a compound equilibrium is preserved between utilization, biosynthesis, and transfer of lipid fractions. Many diseases that affect the parenchyma can lead to changes in the structure of lipoproteins and transport throughout the blood. Nevertheless, in cirrhotic patients, the metabolism of lipid is changed such that glycogen stores are significantly diminished, contributing to malnutrition and biolysis.

NCT ID: NCT04787276 Completed - Liver Cirrhosis Clinical Trials

Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy

Start date: January 10, 2017
Phase: N/A
Study type: Interventional

The purpose of study to assess the short-term efficacy and safety of probiotic E.coli Nissle 1917 strain comparing to lactulose and rifaximin in patients with mild (Stage 1-2) or minimal hepatic encephalopathy

NCT ID: NCT04777344 Completed - Cystic Fibrosis Clinical Trials

Clinical Effort Against Smoke Exposure in Cystic Fibrosis

CEASE-CF
Start date: July 8, 2021
Phase: N/A
Study type: Interventional

The study will test the feasibility, acceptability, and preliminary efficacy of a multi-component smoking cessation intervention tailored to the needs of caregivers of children with CF and delivered in clinical settings as part of routine CF care. The ultimate goal of this effort is to reduce the exposure of children and adolescents with CF to tobacco smoke.

NCT ID: NCT04775277 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Outcome of Idiopathic Pulmonary Fibrosis With Pregnancy

Start date: December 1, 2018
Phase:
Study type: Observational

case-control study was conducted between December 2018 to April 2020. To document outcome of IPF with pregnancy.

NCT ID: NCT04771104 Completed - Liver Cirrhosis Clinical Trials

The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients With Liver Cirrhosis

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Sleep disturbances are common among patients with liver cirrhosis, but the reasons are not well understood. In this project the investigators evaluated whether an increase in blood ammonia in patients with cirrhosis had an impact on sleep quality and the function of retinal ganglion cells measured by pupillary response to blue light.

NCT ID: NCT04759521 Completed - Chronic Hepatitis B Clinical Trials

Evaluation of Liver Fibrosis With 2D-Shear Wave Elastography

Start date: January 3, 2019
Phase:
Study type: Observational [Patient Registry]

The aims of this study are to evaluate liver fibrosis with two-dimensional (2D) shear wave elastography (SWE) technique in inactive hepatitis B surface antigen (HBsAg) carriers and patients with active chronic hepatitis B (CHB), with the help of a propagation map, compare this method with histopathological results in patients with CHB and determine the suitability of 2D-SWE for use instead of liver biopsy by evaluating fibrosis before and after treatment.

NCT ID: NCT04743206 Completed - Cystic Fibrosis Clinical Trials

Airway Clearance for Pediatric and Adult Cystic Fibrosis Patients Using a Portable Intra-Pulmonary Percussion Device

Start date: May 18, 2021
Phase: N/A
Study type: Interventional

This is a pilot study where the investigators aim to compare initial use of the standard airway clearance device (SACD), most commonly used being High frequency vest airway clearance system (VEST) with subsequent use of a Portable Intra-Pulmonary Percussion Device (PIAPD) in patients with cystic fibrosis (CF) ages 6 -21 years. The primary hypothesis is that there is no effect of PIAPD on Forced expiratory volume in 1 second (FEV1) 2 hours after use, there is no effect on perception of effort and efficacy for the PIAPD. If both are equally effective, the latter device provides an alternative that is both cheaper and portable.